Academic literature on the topic 'Pharmaceutical care'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical care.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical care"

1

Chrisp, Paul. "Pharmaceutical care." Inpharma Weekly &NA;, no. 894 (July 1993): 5–6. http://dx.doi.org/10.2165/00128413-199308940-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

KIELGAST, PETER J. "Pharmaceutical care." International Journal of Pharmacy Practice 2, no. 3 (November 1993): 125–26. http://dx.doi.org/10.1111/j.2042-7174.1993.tb00742.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hepler, Charles D. "Pharmaceutical care." Pharmacy World and Science 18, no. 6 (1996): 233–35. http://dx.doi.org/10.1007/bf00735965.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hopefl, Alan W. "Costs of Pharmaceutical Care: Can the Profession do Anything?" Annals of Pharmacotherapy 26, no. 12 (December 1992): 1585–88. http://dx.doi.org/10.1177/106002809202601219.

Full text
Abstract:
OBJECTIVE: To review some of the factors that influence the cost of pharmaceuticals and the delivery of pharmaceutical care as well as some possible measures for decreasing these costs. DATA SYNTHESIS: Clinical studies have been selected to illustrate factors that may add to the overall cost of pharmaceutical care. CONCLUSIONS: Because of the perceived problems resulting from the introduction of new, expensive pharmaceuticals, possible means of controlling the costs of individual products are discussed. In addition, recommendations for achieving cooperation between pharmaceutical manufacturers and pharmacy practitioners in demonstrating the cost-effectiveness of new products are provided.
APA, Harvard, Vancouver, ISO, and other styles
5

Allwood, M. C., C. L. Ronchera-Oms, T. Sizer, B. McElroy, and G. Hardy. "From pharmaceutics to pharmaceutical care in nutritional support." Clinical Nutrition 14, no. 1 (February 1995): 1–3. http://dx.doi.org/10.1016/s0261-5614(06)80002-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bomfim, José Henrique Gialongo Gonçales. "Pharmaceutical Care in Sports." Pharmacy 8, no. 4 (November 16, 2020): 218. http://dx.doi.org/10.3390/pharmacy8040218.

Full text
Abstract:
Pharmaceutical care in sports is a new field of work to clinical pharmacists, focused on promoting pharmacotherapeutic follow up and clinical services to athletes, physical activity practitioners and enthusiasts of any sports modality. A broad range of pharmaceuticals, dietary supplements and herbal drugs have been used historically as performance promoters, doping or ergogenic aids. In this context, the role of pharmacists in prevent adverse events, drug interactions or any drug related problems, as doping issues, was described. Its actions can be important to contribute with a multi professional clinical health team, leading athletes to use these resources in a rational way, promoting and optimizing the therapeutic when its necessary.
APA, Harvard, Vancouver, ISO, and other styles
7

Laven, David L., and William B. Hladik. "Pharmaceutical Care and Diagnostic Pharmaceuticals: Patient Care Avenues Not to Be Overlooked." Journal of Pharmacy Practice 7, no. 3 (June 1994): 79–83. http://dx.doi.org/10.1177/089719009400700302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Manasse, Henri R. "The Care in Pharmaceutical Care." Journal of Pharmacy Teaching 3, no. 3 (1992): 39–52. http://dx.doi.org/10.1300/j060v03n03_06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hill, Peter. "Pharmaceutical care R.I.P?" International Journal of Pharmacy Practice 20, no. 1 (January 11, 2012): 2–3. http://dx.doi.org/10.1111/j.2042-7174.2011.00184.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Morley, P. C. "Pharmaceutical care: desiderata." Journal of Clinical Pharmacy and Therapeutics 18, no. 3 (June 1993): 143–46. http://dx.doi.org/10.1111/j.1365-2710.1993.tb00604.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Pharmaceutical care"

1

Clifford, Rhonda Marise. "Pharmaceutical care in diabetes mellitus." Curtin University of Technology, School of Pharmacy, 2004. http://espace.library.curtin.edu.au:80/R/?func=dbin-jump-full&object_id=14951.

Full text
Abstract:
People with diabetes mellitus are more likely to die from cardiovascular causes than those without diabetes, and modifiable risk factors, such as hyperglycaemia, dyslipidaemia and hypertension can be targeted in intervention programs to decrease this risk. In addition to tertiary care for patients with diabetes, there is a need for simple programs to be implemented in the community that allow the benefits of improved metabolic and blood pressure control to be realised more widely. Pharmaceutical care comprises the detection, prevention and solution of drug-related problems in a quantifiable form, so that outcomes of care can be easily reviewed and monitored. Previous studies of pharmaceutical care programs in patients with diabetes do not provide conclusive evidence of the benefit of pharmaceutical care. The aim of this research was to evaluate the impact of the provision of pharmaceutical care to patients with diabetes mellitus in an Australian context. In order to develop a pharmaceutical care program, the characteristics of an Australian cohort of patients with diabetes were reviewed. The Fremantle Diabetes Study (FDS), was a community-based prospective observational study of diabetes care, control and complications in a postcode-defined region of 120 097 people surrounding the port city of Fremantle in Western Australia. It was intended that the FDS annual reviews would provide important local information in order to design and implement a prospective pharmaceutical care program. A pilot pharmaceutical care program was subsequently developed for use in a diabetes outpatient clinic. This program was then modified for use in a community-based sample of type 2 diabetes mellitus patients, drawn from the FDS cohort.
Demographic parameters, including ethnicity and treatment details, were reviewed at study entry for the full FDS cohort and then over time for a subset of patients that returned for four subsequent annual assessments. Insulin use was more common in patients of Southern European origin compared with the Anglo-Celt group irrespective of the level of glycaemia, at baseline. This difference persisted during subsequent follow-up but was not associated with improved glycaemic control. These findings demonstrated that there are important ethnic differences in the management of patients with type 2 diabetes mellitus. The pilot pharmaceutical care program was carried out in high-risk diabetes mellitus patients attending a hospital outpatient clinic. The patients had poor glycaemic control, dyslipidaemia, hypertension and/or were on three or more prescription medications. In the pharmaceutical care arm, a clinical pharmacist reviewed and monitored all aspects of the patients' drug therapy in collaboration with other health care professionals at six weekly intervals for six months. The control patients received usual outpatient care. Seventy-three patients were recruited into the study, of whom 48 (66%) were randomised to receive pharmaceutical care. One in six patients was taking complementary medicines. The pharmaceutical care program provided patients with important medication information that resulted in changes to drug therapy. However, the six-month program did not lead to an improvement in glycaemic control. The next phase of the study adapted the pilot hospital-based pharmaceutical care program to a community-based setting.
Two hundred and two type 2 diabetes mellitus FDS patients were recruited, of whom 101 (50%) were randomised to the pharmaceutical care program, and all were followed for 12-months. There were significant reductions in risk factors associated with coronary heart disease in the case but not the control group over time, specifically glycaemic control, lipid levels, and blood pressure. Glycosylated haemoglobin fell from 7.5% to 7.0% (P<0.0001), total cholesterol fell from 5 mmol/L to 4.6 mmol/L (P<0.0001), systolic blood pressure fell from 158 mmHg to 143 mmHg (P<0.0001) and diastolic blood pressure fell from 77mmHg to 71mmHg (P<0.0001). Multiple linear regression analysis confirmed that pharmaceutical care program involvement was an independent predictor of benefit after adjustment for key variables. The 10-year coronary heart disease risk for patients without a previous coronary event was reduced by 4.6% over the 12-month study period in the pharmaceutical care group (P<0.0001), while there was no change in the controls (P=0.23). This phase of the study showed that medium-term individualised pharmaceutical care reduced vascular risk factors in a community-based cohort of patients with diabetes and that provision of a multifactorial intervention can improve health outcomes in type 2 diabetes mellitus. As part of the pharmaceutical care program, a high level of complementary medicine use was found. As a result, a study of complementary medicine use was undertaken in 351 patients from the FDS. A convenience sample of FDS patients was interviewed regarding their use of complementary medicines. A literature search was conducted to assess the potential impact of these medicines on diabetes, concomitant medications or diabetes-related co-morbidities.
Eighty-three of 351 (23.6%) patients with diabetes had consumed at least one complementary medicine in the previous year and 42% (77/183) of the products potentially necessitated additional patient monitoring or could be considered potentially inappropriate for a diabetic patient. The data indicated the need for patient disclosure of complementary medicine use and adequate monitoring for complementary medicine-related adverse events, as part of the pharmaceutical care process. The pharmaceutical care model was established to provide a framework by which drug use could be improved to enhance patients' clinical and health-related quality of life outcomes. For the present study, a straightforward pharmaceutical care program was adapted from a hospital setting to a community setting, where the principal requirement was a clinical pharmacist who had completed a self-directed diabetes-training program. In this context, clinically relevant parameters improved over the course of the study period. Pharmaceutical care programs such as this can begin the process of translating the findings of large and expensive clinical trials into standard clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
2

Clifford, Rhonda. "Pharmaceutical care in diabetes mellitus." Thesis, Curtin University, 2004. http://hdl.handle.net/20.500.11937/1907.

Full text
Abstract:
People with diabetes mellitus are more likely to die from cardiovascular causes than those without diabetes, and modifiable risk factors, such as hyperglycaemia, dyslipidaemia and hypertension can be targeted in intervention programs to decrease this risk. In addition to tertiary care for patients with diabetes, there is a need for simple programs to be implemented in the community that allow the benefits of improved metabolic and blood pressure control to be realised more widely. Pharmaceutical care comprises the detection, prevention and solution of drug-related problems in a quantifiable form, so that outcomes of care can be easily reviewed and monitored. Previous studies of pharmaceutical care programs in patients with diabetes do not provide conclusive evidence of the benefit of pharmaceutical care. The aim of this research was to evaluate the impact of the provision of pharmaceutical care to patients with diabetes mellitus in an Australian context. In order to develop a pharmaceutical care program, the characteristics of an Australian cohort of patients with diabetes were reviewed. The Fremantle Diabetes Study (FDS), was a community-based prospective observational study of diabetes care, control and complications in a postcode-defined region of 120 097 people surrounding the port city of Fremantle in Western Australia. It was intended that the FDS annual reviews would provide important local information in order to design and implement a prospective pharmaceutical care program. A pilot pharmaceutical care program was subsequently developed for use in a diabetes outpatient clinic. This program was then modified for use in a community-based sample of type 2 diabetes mellitus patients, drawn from the FDS cohort.Demographic parameters, including ethnicity and treatment details, were reviewed at study entry for the full FDS cohort and then over time for a subset of patients that returned for four subsequent annual assessments. Insulin use was more common in patients of Southern European origin compared with the Anglo-Celt group irrespective of the level of glycaemia, at baseline. This difference persisted during subsequent follow-up but was not associated with improved glycaemic control. These findings demonstrated that there are important ethnic differences in the management of patients with type 2 diabetes mellitus. The pilot pharmaceutical care program was carried out in high-risk diabetes mellitus patients attending a hospital outpatient clinic. The patients had poor glycaemic control, dyslipidaemia, hypertension and/or were on three or more prescription medications. In the pharmaceutical care arm, a clinical pharmacist reviewed and monitored all aspects of the patients' drug therapy in collaboration with other health care professionals at six weekly intervals for six months. The control patients received usual outpatient care. Seventy-three patients were recruited into the study, of whom 48 (66%) were randomised to receive pharmaceutical care. One in six patients was taking complementary medicines. The pharmaceutical care program provided patients with important medication information that resulted in changes to drug therapy. However, the six-month program did not lead to an improvement in glycaemic control. The next phase of the study adapted the pilot hospital-based pharmaceutical care program to a community-based setting.Two hundred and two type 2 diabetes mellitus FDS patients were recruited, of whom 101 (50%) were randomised to the pharmaceutical care program, and all were followed for 12-months. There were significant reductions in risk factors associated with coronary heart disease in the case but not the control group over time, specifically glycaemic control, lipid levels, and blood pressure. Glycosylated haemoglobin fell from 7.5% to 7.0% (P<0.0001), total cholesterol fell from 5 mmol/L to 4.6 mmol/L (P<0.0001), systolic blood pressure fell from 158 mmHg to 143 mmHg (P<0.0001) and diastolic blood pressure fell from 77mmHg to 71mmHg (P<0.0001). Multiple linear regression analysis confirmed that pharmaceutical care program involvement was an independent predictor of benefit after adjustment for key variables. The 10-year coronary heart disease risk for patients without a previous coronary event was reduced by 4.6% over the 12-month study period in the pharmaceutical care group (P<0.0001), while there was no change in the controls (P=0.23). This phase of the study showed that medium-term individualised pharmaceutical care reduced vascular risk factors in a community-based cohort of patients with diabetes and that provision of a multifactorial intervention can improve health outcomes in type 2 diabetes mellitus. As part of the pharmaceutical care program, a high level of complementary medicine use was found. As a result, a study of complementary medicine use was undertaken in 351 patients from the FDS. A convenience sample of FDS patients was interviewed regarding their use of complementary medicines. A literature search was conducted to assess the potential impact of these medicines on diabetes, concomitant medications or diabetes-related co-morbidities.Eighty-three of 351 (23.6%) patients with diabetes had consumed at least one complementary medicine in the previous year and 42% (77/183) of the products potentially necessitated additional patient monitoring or could be considered potentially inappropriate for a diabetic patient. The data indicated the need for patient disclosure of complementary medicine use and adequate monitoring for complementary medicine-related adverse events, as part of the pharmaceutical care process. The pharmaceutical care model was established to provide a framework by which drug use could be improved to enhance patients' clinical and health-related quality of life outcomes. For the present study, a straightforward pharmaceutical care program was adapted from a hospital setting to a community setting, where the principal requirement was a clinical pharmacist who had completed a self-directed diabetes-training program. In this context, clinically relevant parameters improved over the course of the study period. Pharmaceutical care programs such as this can begin the process of translating the findings of large and expensive clinical trials into standard clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
3

Al, Mazroui Nadia. "Pharmaceutical care of type 2 diabetic patients." Thesis, Queen's University Belfast, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.431401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bronkhorst, Elmien. "An Assessment of the need of pharmaceutical services in the intensive care unit and high care unit of Steve Biko Academic hospital." Thesis, University of Limpopo (Medunsa Campus), 2012. http://hdl.handle.net/10386/1081.

Full text
Abstract:
Thesis (MSc(Med)(Pharmacy)) -- University of Limpopo, 2012.
The role of the pharmacist has evolved over the last two decades beyond the traditional functions of dispensing and stock control. The focus has shifted toward patient-oriented functions, in which the pharmacist assumes responsibility for the patient’s drug- and healthcare needs as well as the outcome of treatment. The aim of this research was to assess the need for pharmaceutical care to the Surgical Intensive Care Unit of Steve Biko Hospital. The surgical and trauma ICU is a 12 bed unit to which the researcher rendered pharmaceutical care over an eight week period, from 14 February to 26 March 2011. Interventions to assess drug therapy and achieve definite outcomes to improve patients’ quality of life were documented for 51 study patients according to the system developed by the American Society of Health-System Pharmacists (1992). Of the 51 patients, 35 were male and 16 were female. The age of the patients ranged from 12 years to 86 years, with most patients admitted to the unit in the age groups 21 to 30 years, and 51 to 60 years. The patients’ estimated weights ranged from 40kg to 120kg with older patients, from age 41 upwards, weighing more. The average stay in the unit was 8.7 days, with the minimum stay for one patient being only one day, and the maximum stay for one patient was 26 days. In the study, the HIV status of only 13 of the 51 patients was tested. Of the 13 patients, six were HIV positive, while seven tested negative. All the patients admitted to the unit were not tested for HIV, because they were not admitted to the unit for HIV-related causes, and test results would not have had an effect on their outcome. Diagnoses encountered most frequently in the unit were trauma (21 patients), skeletal involvement or fractures (16 patients), infections or sepsis (15 patients) and gastro-intestinal bleeds (14 patients). In most cases more than one diagnosis applied to the same patient, since patients admitted with trauma also had skeletal or gastro-intestinal involvement. An Assessment of the need of Pharmaceutical Services in the Intensive Care Unit and High Care Unit of Steve Biko Academic Hospital viii The medications prescribed most frequently were enoxaparin (49 patients), sucralfate (41 patients) and multivitamin syrup (47 patients); in accordance with the standard ward protocol for prophylactic regimens. The drug class most often used was the anti-infectiveshaving124 items prescribed during the study period. Of these, the broad spectrum antibiotics were used most frequently, e.g. piperacillin/tazobactam (22 patients), meropenem (11 patients) and imipenem (11 patients). An average of 12 medications was prescribed for each patient in the ward. A total of 181 interventions were suggested for the 51 patients during the study period, of which 127 (70%) were accepted and implemented by the medical and nursing staff. The average number of interventions per patient ranged from 0 to 13 with a median of 3.5 interventions per patient. The four most frequent problem types were untreated medical conditions (15.5%), length or course of therapy inappropriate (13.8%), investigations indicated or outstanding (12.2%) and prescribed doses and dosing frequency appropriate (11%). Interventions were also made regularly to address system errors or non-compliance and factors hindering achievement of therapeutic effect. The perceived need for pharmaceutical care by healthcare professionals in the SICU was measured by questionnaires before and after the study period. The feedback by staff regarding the pharmacist working in the ward was very positive. They appreciated the researchers input on ward rounds, as well as assistance with problems encountered with the pharmacy. Of the total time spent in the ward, the researcher spent 28% of her time on patient evaluation. Ward rounds also took up a great deal of time (21.7%), since ward rounds were done with different members of the multidisciplinary team. Most interventions were suggested during ward rounds. The costs saved during the study period were enough to justify the appointment of a pharmacist to the ward on a permanent basis, albeit for limited hours daily. The researcher designed an antibiotic protocol for the unit. The protocol was designed according to international standards, and after discussion with the microbiologists, adapted for use in the specific unit. An Assessment of the need of Pharmaceutical Services in the Intensive Care Unit and High Care Unit of Steve Biko Academic Hospital ix In conclusion, the study results have demonstrated that a pharmacist’s contribution to patient care at ward level in a surgical ICU resulted in clinical outcomes that improved the patient’s quality of life. Drug-related problems were identified and addressed. Medical staff in the S-ICU accepted the pharmacist’s interventions and even welcomed her contribution to other ward functions, for instance managing medication and providing education. Pharmaceutical care should be rendered on a permanent basis to the Surgical ICU and the pharmacist should increasingly become a key part of the multidisciplinary team, taking responsibility for patients’ medication needs.
APA, Harvard, Vancouver, ISO, and other styles
5

Varma, Sumanthra. "Pharmaceutical care of elderly congestive heart failure patients." Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sturgess, Ian K. "Pharmaceutical care provision to community dwelling elderly patients." Thesis, Queen's University Belfast, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sadik, A. S. "Pharmaceutical care of patients with congestive heart failure." Thesis, Queen's University Belfast, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scanlan, Justine Claire. "Pharmaceutical care for cancer patients : a multidisciplinary approach." Thesis, University College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.289814.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stern, Philip. "Patterns of pharmaceutical prescribing." Thesis, London Business School (University of London), 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.309363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Glynn, Caroline. "Aspects of pharmaceutical care provision by the community pharmacist." Thesis, Queen's University Belfast, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.337033.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmaceutical care"

1

Penna, Richard P., and Calvin H. Knowlton. Pharmaceutical care. 2nd ed. Bethesda, MD: American Society of Health-System Pharmacists, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

J, Cipolle Robert, Morley Peter C, and Cipolle Robert J, eds. Pharmaceutical care practice. 3rd ed. New York: McGraw-Hill, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

M, Strand Linda, and Morley Peter C, eds. Pharmaceutical care practice. New York: McGraw-Hill, Health Professions Division, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Interpersonal communication in pharmaceutical care. New York: Pharmaceutical Products Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Galt, Kimberly A. Clinical skills program: Advancing pharmaceutical care. Bethesda, MD: American Society of Hospital Pharmacists, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

N, Tindall William, and Millonig Marsha K, eds. Pharmaceutical care: Insights from community pharmacists. Boca Raton: CRC Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

P, Rovers John, ed. A practical guide to pharmaceutical care. Washington, D.C: American Pharmaceutical Association, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

P, Rovers John, ed. A practical guide to pharmaceutical care. 2nd ed. Washington, D.C: American Pharmaceutical Association, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

R, Moore Steven, ed. Geriopharmacotherapy in home health care: New frontiers in pharmaceutical care. New York: Haworth Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

C, Smith Mickey, and Wertheimer Albert I, eds. Social and behavioral aspects of pharmaceutical care. New York: Pharmaceutical Products Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmaceutical care"

1

Westerlund, Tommy. "Documenting Pharmaceutical Care." In The Pharmacist Guide to Implementing Pharmaceutical Care, 89–94. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Khatri, Naresh. "Pharmaceutical Companies." In Crony Capitalism in US Health Care, 38–44. New York: Routledge, 2021. http://dx.doi.org/10.4324/9781003112204-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alves da Costa, Filipa. "Pharmaceutical Care in Europe." In The Pharmacist Guide to Implementing Pharmaceutical Care, 159–71. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lee, Shaun Wen Huey, and J. Simon Bell. "Pharmaceutical Care in Asia." In The Pharmacist Guide to Implementing Pharmaceutical Care, 191–97. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moles, Rebekah, and Stephen Carter. "Pharmaceutical Care in Pediatrics." In The Pharmacist Guide to Implementing Pharmaceutical Care, 381–95. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Alves da Costa, Filipa, and Kurt E. Hersberger. "Paying for Pharmaceutical Care." In The Pharmacist Guide to Implementing Pharmaceutical Care, 461–66. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Marinkovic, Valentina, Marina Odalovic, Ivana Tadic, Dusanka Krajnovic, Irina Mandic, and Heather L. Rogers. "Person-Centred Care Interventions in Pharmaceutical Care." In Intelligent Systems for Sustainable Person-Centered Healthcare, 53–68. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-79353-1_4.

Full text
Abstract:
AbstractThis chapter is divided into four sections. The first section introduces the concept of person-centred care within pharmaceutical care delivery and provides a historical context. The second section focuses on the professionals and explores the role of person-centred pharmaceutical care as part of multi-disciplinary health services delivery teams. The third section focuses on the patient and describes the role of health literacy in the implementation of person-centred pharmaceutical care. The last section examines E-pharmacy services and the implementation of telepharmacy with implications for person-centred care.
APA, Harvard, Vancouver, ISO, and other styles
8

Abbott, Thomas A. "Regulating Pharmaceutical Prices." In Health Care Policy and Regulation, 105–41. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-2219-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nahler, Gerhard. "health care expenditure." In Dictionary of Pharmaceutical Medicine, 85. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_634.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nahler, Gerhard. "health care services." In Dictionary of Pharmaceutical Medicine, 85. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_635.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical care"

1

Nascimento, A., S. R. Castilho, R. M. V. R. Almeida, and A. F. C. Infantosi. "Evaluating pharmaceutical assistance activities in Brazilian hospitals." In 2011 Pan American Health Care Exchanges (PAHCE 2011). IEEE, 2011. http://dx.doi.org/10.1109/pahce.2011.5871863.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Costa, Wanderson, José Rafael Nascimento, Elisa Menendez, Marcos Dósea, Leila Silva, Monique Jabbur, Ana Patrícia Lima, and Divaldo Lyra Junior. "A system to help the teaching of pharmaceutical care." In the 6th Euro American Conference. New York, New York, USA: ACM Press, 2012. http://dx.doi.org/10.1145/2261605.2261620.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Arroyo-Jiménez, María Del Mar, Sara Mínguez, Jose Antonio Carbajal, Lucía Castro-Vázquez, Joaquïn González-Fuentes, and Gema Blázquez-Abellán. "II WORKSHOP OF PHARMACEUTICAL CARE OF PARKINSON'S DISEASE PATIENTS." In 11th annual International Conference of Education, Research and Innovation. IATED, 2018. http://dx.doi.org/10.21125/iceri.2018.1916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Farida, Yeni, Katarina Puspita, and Zahra Yusvida. "Empirical Antibiotics Study on Pneumonia in Intensive Care Unit." In 1st Muhammadiyah International Conference on Health and Pharmaceutical Development. SCITEPRESS - Science and Technology Publications, 2018. http://dx.doi.org/10.5220/0008239200480053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Quirós, V. Saavedra, R. Capilla Pueyo, I. Roch Hamelin, A. Medina Carrizo, MA Gómez Mateos, and A. Sánchez Guerrero. "4CPS-255 Expanding the process of pharmaceutical care to the institutionalised patient care unit." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gruenwald, G., and T. Lee. "164. Glutaraldehyde Exposures after Disinfectant Fogging in Pharmaceutical Aseptic Rooms: Evaluation and Control." In AIHce 1996 - Health Care Industries Papers. AIHA, 1999. http://dx.doi.org/10.3320/1.2764825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

J., Camellia, Pramestutie H. R., and Hariadini A. L. ""Diarrhea Care Program" as Effective Pediatric Diarrhea Counseling Tool for Pharmacy Practice." In Annual International Conference on Pharmacology and Pharmaceutical Sciences. Global Science & Technology Forum (GSTF), 2014. http://dx.doi.org/10.5176/2345-783x_pharma14.27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hirano, Luciano Roberto, Silvio Bortoleto, Claudia Seiko Yokoyama, and Hugo Bulegon. "An information system for drug interactions: pharmaceutical care and prescription." In 2009 World Congress on Nature & Biologically Inspired Computing (NaBIC 2009). IEEE, 2009. http://dx.doi.org/10.1109/nabic.2009.5393548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Morera, D. Briegas, C. Bonilla Galán, C. Meneses Mangas, E. García Lobato, J. Pardal, LM Bravo García-Cuevas, S. Martín Clavo, R. Medina Comas, and JF Rangel Mayoral. "DI-001 Making pharmaceutical care easy by designing interactive software." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Redondo Galán, C., MD Rivas Rodríguez, D. González Vaquero, M. Ferris Villanueva, and JF Rangel Mayoral. "4CPS-373 Pharmaceutical care in hospitalisation units: analysis of interventions." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.205.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical care"

1

Zhong, Lirong, Alexandre V. Mitroshkov, and Tyler J. Gilmore. Analysis of Pharmaceutical and Personal Care Compounds in Wastewater Sludge and Aqueous Samples using GC-MS/MS. Office of Scientific and Technical Information (OSTI), March 2016. http://dx.doi.org/10.2172/1242343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mitroshkov, Alexandre V., Lirong Zhong, and Linda M. P. Thomas. Analysis of Perfluorinated, Pharmaceutical, Personal Care Compounds and Heavy Metals in Waste Water Sludge using GC-MS/MS and Multicollector ICP-MS. Office of Scientific and Technical Information (OSTI), January 2019. http://dx.doi.org/10.2172/1494304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lucarelli, Claudio, Sean Nicholson, and Minjae Song. Bundling Among Rivals: A Case of Pharmaceutical Cocktails. Cambridge, MA: National Bureau of Economic Research, August 2010. http://dx.doi.org/10.3386/w16321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Huber, Sandra, Mikael Remberger, Arntraut Goetsch, Kirsten Davanger, Lennart Kaj, Dorte Herzke, Martin Schlabach, et al. Pharmaceuticals and additives in personal care products as environmental pollutants. Nordic Council of Ministers, August 2013. http://dx.doi.org/10.6027/tn2013-541.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chan, Leong. Developing a Strategic Policy Choice Framework for Technological Innovation: Case of Chinese Pharmaceuticals. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.1041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Peters, Joseph. Pharmaceutical Contaminants as Stressors on Rocky Intertidal and Estuarine Organisms: a Case Study of Fluoxetine. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Feliciano, Zadia, and Meng-Ting Chen. Intangible Assets, Corporate Taxes and the Relocation of Pharmaceutical Establishments: The case of Puerto Rico. Cambridge, MA: National Bureau of Economic Research, July 2021. http://dx.doi.org/10.3386/w29107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chaudhuri, Shubham, Pinelopi Goldberg, and Panle Jia. Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India. Cambridge, MA: National Bureau of Economic Research, December 2003. http://dx.doi.org/10.3386/w10159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hajarizadeh, Behzad, Jennifer MacLachlan, Benjamin Cowie, and Gregory J. Dore. Population-level interventions to improve the health outcomes of people living with hepatitis B: an Evidence Check brokered by the Sax Institute for the NSW Ministry of Health, 2022. The Sax Institute, August 2022. http://dx.doi.org/10.57022/pxwj3682.

Full text
Abstract:
Background An estimated 292 million people are living with chronic hepatitis B virus (HBV) infection globally, including 223,000 people in Australia. HBV diagnosis and linkage of people living with HBV to clinical care is suboptimal in Australia, with 27% of people living with HBV undiagnosed and 77% not receiving regular HBV clinical care. This systematic review aimed to characterize population-level interventions implemented to enhance all components of HBV care cascade and analyse the effectiveness of interventions. Review questions Question 1: What population-level interventions, programs or policy approaches have been shown to be effective in reducing the incidence of hepatitis B; and that may not yet be fully rolled out or evaluated in Australia demonstrate early effectiveness, or promise, in reducing the incidence of hepatitis B? Question 2: What population-level interventions and/or programs are effective at reducing disease burden for people in the community with hepatitis B? Methods Four bibliographic databases and 21 grey literature sources were searched. Studies were eligible for inclusion if the study population included people with or at risk of chronic HBV, and the study conducted a population-level interventions to decrease HBV incidence or disease burden or to enhance any components of HBV care cascade (i.e., diagnosis, linkage to care, treatment initiation, adherence to clinical care), or HBV vaccination coverage. Studies published in the past 10 years (since January 2012), with or without comparison groups were eligible for inclusion. Studies conducting an HBV screening intervention were eligible if they reported proportion of people participating in screening, proportion of newly diagnosed HBV (participant was unaware of their HBV status), proportion of people received HBV vaccination following screening, or proportion of participants diagnosed with chronic HBV infection who were linked to HBV clinical care. Studies were excluded if study population was less than 20 participants, intervention included a pharmaceutical intervention or a hospital-based intervention, or study was implemented in limited clinical services. The records were initially screened by title and abstract. The full texts of potentially eligible records were reviewed, and eligible studies were selected for inclusion. For each study included in analysis, the study outcome and corresponding 95% confidence intervals (95%CIs) were calculated. For studies including a comparison group, odds ratio (OR) and corresponding 95%CIs were calculated. Random effect meta-analysis models were used to calculate the pooled study outcome estimates. Stratified analyses were conducted by study setting, study population, and intervention-specific characteristics. Key findings A total of 61 studies were included in the analysis. A large majority of studies (study n=48, 79%) included single-arm studies with no concurrent control, with seven (12%) randomised controlled trials, and six (10%) non-randomised controlled studies. A total of 109 interventions were evaluated in 61 included studies. On-site or outreach HBV screening and linkage to HBV clinical care coordination were the most frequent interventions, conducted in 27 and 26 studies, respectively. Question 1 We found no studies reporting HBV incidence as the study outcome. One study conducted in remote area demonstrated that an intervention including education of pregnant women and training village health volunteers enhanced coverage of HBV birth dose vaccination (93% post-intervention, vs. 81% pre-intervention), but no data of HBV incidence among infants were reported. Question 2 Study outcomes most relevant to the HBV burden for people in the community with HBV included, HBV diagnosis, linkage to HBV care, and HBV vaccination coverage. Among randomised controlled trials aimed at enhancing HBV screening, a meta-analysis was conducted including three studies which implemented an intervention including community face-to-face education focused on HBV and/or liver cancer among migrants from high HBV prevalence areas. This analysis demonstrated a significantly higher HBV testing uptake in intervention groups with the likelihood of HBV testing 3.6 times higher among those participating in education programs compared to the control groups (OR: 3.62, 95% CI 2.72, 4.88). In another analysis, including 25 studies evaluating an intervention to enhance HBV screening, a pooled estimate of 66% of participants received HBV testing following the study intervention (95%CI: 58-75%), with high heterogeneity across studies (range: 17-98%; I-square: 99.9%). A stratified analysis by HBV screening strategy demonstrated that in the studies providing participants with on-site HBV testing, the proportion receiving HBV testing (80%, 95%CI: 72-87%) was significantly higher compared to the studies referring participants to an external site for HBV testing (54%, 95%CI: 37-71%). In the studies implementing an intervention to enhance linkage of people diagnosed with HBV infection to clinical care, the interventions included different components and varied across studies. The most common component was post-test counselling followed by assistance with scheduling clinical appointments, conducted in 52% and 38% of the studies, respectively. In meta-analysis, a pooled estimate of 73% of people with HBV infection were linked to HBV clinical care (95%CI: 64-81%), with high heterogeneity across studies (range: 28-100%; I-square: 99.2%). A stratified analysis by study population demonstrated that in the studies among general population in high prevalence countries, 94% of people (95%CI: 88-100%) who received the study intervention were linked to care, significantly higher than 72% (95%CI: 61-83%) in studies among migrants from high prevalence area living in a country with low prevalence. In 19 studies, HBV vaccination uptake was assessed after an intervention, among which one study assessed birth dose vaccination among infants, one study assessed vaccination in elementary school children and 17 studies assessed vaccination in adults. Among studies assessing adult vaccination, a pooled estimate of 38% (95%CI: 21-56%) of people initiated vaccination, with high heterogeneity across studies (range: 0.5-93%; I square: 99.9%). A stratified analysis by HBV vaccination strategy demonstrated that in the studies providing on-site vaccination, the uptake was 78% (95%CI: 62-94%), significantly higher compared to 27% (95%CI: 13-42%) in studies referring participants to an external site for vaccination. Conclusion This systematic review identified a wide variety of interventions, mostly multi-component interventions, to enhance HBV screening, linkage to HBV clinical care, and HBV vaccination coverage. High heterogeneity was observed in effectiveness of interventions in all three domains of screening, linkage to care, and vaccination. Strategies identified to boost the effectiveness of interventions included providing on-site HBV testing and vaccination (versus referral for testing and vaccination) and including community education focussed on HBV or liver cancer in an HBV screening program. Further studies are needed to evaluate the effectiveness of more novel interventions (e.g., point of care testing) and interventions specifically including Indigenous populations, people who inject drugs, men who have sex with men, and people incarcerated.
APA, Harvard, Vancouver, ISO, and other styles
10

Pandey, A., N. Bhattarai, B. ,. Adhikary, B. Karky, C. P. Pokhrel, and A. Pathak. Baseline Study of Endocrine-Disrupting Compounds and Pharmaceuticals and Personal Care Products in Waterways Surrounding Chitwan National Park, Nepal; Field Report 2018. Kathmandu, Nepal: International Centre for Integrated Mountain Development (ICIMOD), 2018. http://dx.doi.org/10.53055/icimod.713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography